Abstract
A human immunodeficiency virus (HIV)-infected individual was first diagnosed with red blood cell aplasia due to B19 parvovirus infection in late 1989. Over the subsequent seven-year period, he received a total of 119 units of red blood cells (RBCs) and intravenous immunoglobulin every 2-3 weeks. In 1996 combination antiretroviral treatment with a protease inhibitor was initiated. He received four more units during the following two months and then required no more transfusions for the subsequent 24 months of follow- up. His CD4 count progressively increased and DNA polymerase chain reaction for parvovirus B19 became undetectable. Aggressive antiretroviral treatment may effectively diminish transfusion requirements among HIV-infected individuals with pure RBC aplasia resulting from parvovirus B19 infection.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 164-166 |
| Number of pages | 3 |
| Journal | American Journal of Hematology |
| Volume | 60 |
| Issue number | 2 |
| DOIs | |
| State | Published - 1999 |
Keywords
- AIDS
- Anemia
- B-19 parvovirus
- HIV
- Protease inhibitor
- Pure red cell apiasia
ASJC Scopus subject areas
- Hematology
Fingerprint
Dive into the research topics of 'Persistent parvovirus B19 related anemia of seven years' duration in an HIV-infected patient: Complete remission associated with highly active antiretroviral therapy'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS